“Global Human Microbiome Therapeutics market set to grow to $1bn by 2024” says new Visiongain report

24 April 2019
Pharma

Visiongain has published a new pharma report Global Human Microbiome Therapeutics Market Forecast 2019-2029: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

A specialist sector within the overall pharmaceutical industry, the human microbiome-therapeutic market is dominated by a relatively small number of companies. The market holds enormous opportunities for growth in key therapeutic areas. Some of the Phase III drugs are expected to be launched in the first half of the forecast period while few Phase II drugs are expected to be launched in second half of the forecast period. We expect growth in all key sectors of the market during the forecast period.

This report profiled the selected companies: 4D Pharma, AOBiome Therapeutics, C3J Therapeutics, Caelus Health, Enterome Bioscience, Ferring Pharmaceuticals, Finch Therapeutics/Crestovo, IGEN BIOTECH GROUP, Immuron, Intrexon Corporation, MaaT Pharma, MatriSys Biosystem and other companies.

The lead analyst commented that "The prime opportunity for microbiome therapeutics is to fulfil the unmet clinical needs in various indications. The current therapies in some of the indication may provide symptomatic relief but cannot cure the disease or have adverse side effects. The microbiome industry is in nascent stage but developing rapidly. The first human microbiome therapeutics is expected to launch in 2020. Various clinical data suggests that the use of microbiome-based therapies is likely to cause fewer side effects than the use of traditional pharmaceuticals, further enhancing their market potential."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever